Basilea Pharmaceutica - Third leg of strategy executed with debt repayment
Basilea has announced the full repayment of the CHF113.8m outstanding amount under its 2.75% convertible bonds due on 23 December 2022, supported...
670 Views
Basilea Pharmaceutica - Oncology milestone payment triggered
As expected, Basilea continues to derive value from its oncology exit as it has received a transition-related milestone payment of US$4m (CHF3.7m)...
670 Views
Basilea Pharmaceutica - Third oncology asset sale announced, as planned
Basilea announced another successful oncology asset sale as a part of its strategic plan to focus on its core anti-infectives business. The company...
334 Views
Basilea Pharmaceutica - New supportive data from ERADICATE
Basilea Pharmaceutica has presented detailed data from the Phase III ERADICATE study of Zevtera (ceftobiprole) in the treatment of Staphylococcus...
664 Views
Basilea Pharmaceutica - Oncology asset sales continue
Basilea Pharmaceutica continues its positive wave of Q322 activity with the successful asset purchase and sub-licence agreement of its tyrosine...
674 Views